Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-40,000
Closed -$4.96M 363
2023
Q4
$4.96M Hold
40,000
0.11% 109
2023
Q3
$3.73M Hold
40,000
0.08% 114
2023
Q2
$5.14M Hold
40,000
0.1% 103
2023
Q1
$4.65M Hold
40,000
0.1% 144
2022
Q4
$4.53M Hold
40,000
0.08% 266
2022
Q3
$3.22M Hold
40,000
0.04% 439
2022
Q2
$2.98M Sell
40,000
-16,000
-29% -$1.46M 0.03% 501
2022
Q1
$7.16M Buy
56,000
+22,000
+65% +$2.41M 0.06% 340
2021
Q4
$4.56M Buy
34,000
+10,000
+42% +$1.44M 0.04% 406
2021
Q3
$3.28M Buy
+24,000
New +$3.03M 0.03% 406

Other funds holding DXCM

Sculptor Capital's DXCM Position: Q2 2023 in Review

Sculptor Capital sold out of DexCom (DXCM) in Q2 2023, closing a stake of 17,848 shares — an estimated $2.16M sold.

Sculptor Capital first reported a position in DXCM in Q3 2021 and held it in 7 quarters. The position peaked at $8.65M in Q4 2021. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

  • Sculptor Capital reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
  • Sculptor Capital sold 17,848 DexCom shares in Q2 2023, an estimated $2.16M.
  • Sculptor Capital first reported a position in DexCom in Q3 2021 and held it in 7 quarters.
  • Sculptor Capital's DexCom position peaked at $8.65M in Q4 2021.
  • 954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on Sculptor Capital's 13F filing for Q2 2023, filed 14 Aug 2023.